Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details) $ in Thousands, £ in Millions	1 Months Ended		3 Months Ended		6 Months Ended			12 Months Ended				19 Months Ended
Revenue (Details) $ in Thousands, £ in Millions	Jun. 30, 2014 GBP (£)	Jun. 30, 2014 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2016 USD ($)	Jun. 30, 2016 USD ($) Milestone item	Jun. 30, 2015 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2015 GBP (£)	Dec. 31, 2015 USD ($)
Collaboration and License Agreement
Revenue recognized			$ 328	$ 2,783		$ 3,246	$ 5,511
Collaborative arrangement \| GlaxoSmithKline Intellectual Property Development Ltd
Collaboration and License Agreement
Number of additional target peptides, that the entity has right to nominate \| item						4
Upfront payment received	£ 25	$ 42,000
Milestone payments received												£ 14	$ 22,000
Number of milestones achieved during the period \| Milestone						0
Revenue recognized			328	$ 2,783		$ 3,246	$ 5,511
Collaborative arrangement \| GlaxoSmithKline Intellectual Property Development Ltd \| Change in service delivery period in collaboration and license agreement \| Adjustment
Collaboration and License Agreement
Revenue recognized			$ (2,785)
Collaborative arrangement \| GlaxoSmithKline Intellectual Property Development Ltd \| Change in service delivery period in collaboration and license agreement \| Forecast adjustment
Collaboration and License Agreement
Revenue recognized					$ (672)			$ 1,642	$ 1,187	$ 1,793	$ (1,344)